Brief: Calidi Biotherapeutics Inc Says Co Entered Into Sales Agreement With Ladenburg Thalmann & Co. Inc
11/10/2024 23:03
Oct 11 (Reuters) - Calidi Biotherapeutics Inc CLDI.A :
* CALIDI BIOTHERAPEUTICS INC: CO ENTERED INTO SALES
AGREEMENT
WITH LADENBURG THALMANN & CO. INC
* CALIDI BIOTHERAPEUTICS INC: UNDER THE AGREEMENT, CO TO
SELL
SHARES OF ITS COMMON STOCK HAVING AN AGGREGATE OFFERING PRICE OF
UP TO $5.1 MILLION
Source text for Eikon: ID:n0001493152-24-040953
Further company coverage: CLDI.A
((Reuters.Brief@thomsonreuters.com;))
Recent news on Calidi Biotherapeutics
See all newsBrief: Calidi Biotherapeutics Announces Strategic Partnership With Transferai
Brief: Calidi Biotherapeutics Announces Partnership With Avance Clinical To Facilitate Australian Regulatory Approval
Brief: Calidi Biotherapeutics Announces Pricing Of $5.2 Million Underwritten Public Offering
Brief: Calidi Biotherapeutics Eliminates Chief Legal Officer Position - SEC Filing
Brief: Calidi Biotherapeutics Receives FDA Fast Track Designation For Cld-201 (Supernova), A First-In-Class Stem-Cell Loaded Viral Therapy For The Treatment Of Patients With Soft Tissue Sarcoma